Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST) Meeting Abstract
| Authors: | Heinrich, M. C.; Somaiah, N.; Trent, J. C.; Wilky, B. A.; Burgess, M. A.; Singh, A. S.; Attia, S.; Agulnik, M.; Tap, W. D.; Bauer, S.; Jones, R. L.; Serrano, C.; Zou, L.; Moynihan, K.; Lawrence, J.; Wagner, A. J. |
| Abstract Title: | Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST) |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500736 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.TPS766 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS766 -- Source: Wos |
